Ann DeWitt

Ann DeWitt is a General Partner at Engine Ventures, where they invest in seed through Series B and other early-stage venture rounds across biotechnology, life sciences, artificial intelligence, and big data. They invest in companies in the United States, with a focus on Greater Boston, the East Coast, and New England. DeWitt serves on the boards of ImmuneXcite and WEST (Women in the Enterprise of Science and Technology), and has invested in companies including Bexorg, Predicta Biosciences, Vaxess Technologies, Kano Therapeutics, and Droplet Biosciences. Before Engine Ventures, DeWitt was a General Partner and COO at The Engine; earlier roles include Senior Director positions at Sanofi and Sanofi-Genzyme BioVentures, Senior Director of Corporate Development at Permeon Biologics, Senior Associate at Flagship Ventures, and positions at 3M Company and the University of Minnesota, as well as serving with Springboard Enterprises and WEST. DeWitt attended Harvard Business School and lives in Cambridge, Massachusetts.